GUELPH, ON, June 29 /PRNewswire-FirstCall/ - BIOREM Inc. ("Biorem" or "the Company") (TSX-V: BRM), a leading clean technology company that designs and supplies high-efficiency biological-based air emissions control systems, announced today the receipt of two separate orders for odor control systems totalling $2.3 million.
The first order is for a large scale four cell biofilter designed to treat air emissions from a wastewater treatment plant and biosolids processing building located in the Greater Toronto Area. The second order is for a biotrickling filter treating hydrogen sulfide at a wastewater treatment plant in the southeastern region of the United States.
"Our growth in recent years is a strong endorsement of our technology, its efficiency, low maintenance requirements and superior performance and economics," said Peter Bruijns, President and CEO. "We lead the industry in biological odor abatement and are confident that the implementation of our systems will have a very positive impact on the quality of life and potentially the property values of residences in these areas. It is rewarding to have our technology adopted both locally and around the world."
About BIOREM Inc.
Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency biological-based air emissions control systems. These systems are used to eliminate odors, volatile organic compounds (VOCs) and hazardous air pollutants (HAPs), and for the conditioning of biogas renewable energy. With sales and manufacturing offices across the continent, a dedicated research facility, a worldwide sales representative network and more than 600 installed systems worldwide, Biorem not only offers state-of-the-art technology-based products but also peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on Biorem is available on our website at www.biorem.biz.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This press release contains forward-looking statements based on current expectations. These forward-looking statements contain various risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Risks and uncertainties about the Company's business are more fully discussed in the disclosure materials, financial statements and MD&A filed with the securities regulatory authorities in Canada on www.sedar.com
"Order Bookings" and "Order Backlog" do not have any standardized meaning prescribed by Canadian generally accepted accounting principles ("GAAP") and may not be comparable to measures presented by other companies.
Order Bookings and Order Backlog are non-GAAP measures that the Company uses to evaluate its sales performance. Order Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. As Order Bookings are received, the contract value (before any associated sales taxes) is included in the Order Backlog. The Order Backlog is reduced by the revenue that is recognized on each project.
SOURCE Biorem Inc.